When I started taking Ozempic in 2020, it felt niche. The zeitgeist hadn't caught on yet—it was simply a medication prescribed by my board-certified endocrinologist. Fast-forward to 2026, and I know more people taking or at least talking about Ozempic—or another member of the GLP-1 family—than people who aren't. In just a few short years, these injectable peptide medications have completely reshaped the weight loss conversation. The overwhelming positives—highly effective treatment options for obesity, PCOS, and metabolic dysfunction—sit uncomfortably close to the negatives, including medication misuse, unrealistic body standards, and today's renewed obsession with thinness. But perhaps the most concerning development is the booming underground peptide market that's rapidly gaining momentum.
The reason for the rev-up? Retatrutide, the next-generation GLP-1 that's generating enormous buzz despite not yet being FDA-approved. "Semaglutide opened the door, Tirzepatide raised the bar, and Retatrutide might be the next overachiever in the GLP world," says board-certified physician associate and Goldhaus founder Jill Villa.
